Bayer tries to revive patent term extension for contraceptive drug

Bayer 2022-03-03 10:00 pm By Cat Fredenburgh | Melbourne

Please login to bookmark

Bayer says the patents office was wrong to quash an extension for its patent covering an oral contraceptive on the grounds that its application should have been based on a drug with an earlier approval date.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au